INVESTORS & MEDIA
Raymond Schinazi Joins Precision BioSciences Board of Directors
DURHAM, North Carolina, USA, March 14, 2019 –
Precision BioSciences (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, has appointed Raymond Schinazi, PhD, Hon DSc to its board of directors. Dr. Schinazi is the Frances Winship Walters Professor of Pediatrics and director of the Laboratory of Biochemical Pharmacology at Emory University.
“The cutting-edge technology developed by the Precision BioSciences team provides new opportunities to combat viral diseases like hepatitis B virus (HBV),” said Dr. Schinazi. “Their proprietary genome editing platform, ‘ARCUS,’ has the potential to enable alternative innovative therapies to safely and efficiently silence genes essential for viruses that cause significant human morbidity and mortality.”
“Dr. Schinazi’s expertise in virology and preclinical and clinical drug development will be invaluable as our company continues the development of our platform to tackle the problem of HBV and other viruses,” said Precision CEO Matt Kane. “His dedication to addressing unmet need in viral disease and his understanding of ARCUS at the mechanistic level make him an ideal board member as we work to build an innovative antiviral genome editing program.”
Dr. Schinazi’s distinguished career in drug discovery includes co-founding several biotechnology companies, including Triangle Pharmaceuticals and Pharmasset, Inc. He is also a Charter Fellow of the National Academy of Inventors and a Fellow of the American Society of Microbiology. He received a BSc and PhD in chemistry and DSc in biotechnology from the University of Bath. Dr. Schinazi also serves on the board of directors of Brace Pharma Capital and the board of trustees of amfAR.
About Precision BioSciences
Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, “ARCUS.” Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For additional information, please visit www.precisionbiosciences.com